Determination of the biological variation of S100β and lactate dehydrogenase in disease-free patients with malignant melanoma

被引:5
|
作者
Trape, Jaume [1 ]
Montesinos, Jesus [2 ]
Franquesa, Josefina [1 ]
Sala, Maria [1 ]
Figols, Cristina [1 ]
Miguel, Ana [2 ]
Domenech, Montserrat [2 ]
机构
[1] Althaia Xarxa Assistencial Manresa, Serv Clin Chem, Dept Biol Diag, Manresa 08243, Catalonia, Spain
[2] Althaia Xarxa Assistencial Manresa, Serv Oncol, Manresa 08243, Catalonia, Spain
关键词
analytical goals; biological variation; LDH; reference change value; S100; SERUM CONSTITUENTS; LONG-TERM; CANCER;
D O I
10.1515/CCLM.2012.799
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Biological variation is important for determining analytical goals and for establishing the magnitude of change between two consecutive measurements. The aim of this study was to determine the biological variation for S100 beta and lactate dehydrogenase in patients diagnosed with malignant melanoma but without evidence of disease recurrence. Methods: The biological variation of S100 beta and lactate dehydrogenase was estimated from a mean of four consecutive measurements in 32 patients diagnosed with malignant melanoma but without evidence of disease recurrence, 3 months after tumor resection or 4 months after finishing adjuvant treatment. The mean sampling interval was 3 months. Results: Mean concentrations of S100 beta and lactate dehydrogenase were 0.0557 mu g/L and 6.3 mu kat/L, respectively. Between-run analytical variation was 3.5% at 0.181 mu g/L for S100 beta and 3.5% at 2.83 mu kat/L for lactate dehydrogenase. Biological variations obtained for S100 beta and lactate dehydrogenase were 14.2% and 8.2%, respectively. The analytical goals (defined as 50% of biological variation) were 7.1% for S100 beta and 4.1% for lactate dehydrogenase. Conclusions: The estimation of biological variation allows us to calculate analytical goals and reference change values. These are necessary tools for the correct interpretation of serial measurements in patient follow-up.
引用
收藏
页码:927 / 929
页数:3
相关论文
共 50 条
  • [21] S100 IRMA: A new and prognostic tumor marker in patients with malignant melanoma.
    Brenner, W
    Hauschild, A
    Engel, G
    Bohuslavizki, KH
    Monig, H
    Christophers, E
    Henze, E
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (05) : 600 - 600
  • [22] Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status
    Frauchiger, A. L.
    Mangana, J.
    Rechsteiner, M.
    Moch, H.
    Seifert, B.
    Braun, R. P.
    Dummer, R.
    Goldinger, S. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 174 (04) : 823 - 830
  • [23] Disease-free survival and survival after metastases of 202 patients with metastatic malignant melanoma
    Roller, E
    Ruzicka, T
    Schulte, KW
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (03) : A80 - A80
  • [24] Serum S100, melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in stage IV melanoma patients treated with biochemotherapy
    Cao, Maria Gonzalez
    Malvhey, Josep
    Auge, Jose Maria
    Marti, Rosa
    Castel, Teresa
    Molina, Rafael
    Puig, Susana
    ANNALS OF ONCOLOGY, 2004, 15 : 204 - 204
  • [25] Erratum to: S-100B Concentrations Predict Disease-Free Survival in Stage III Melanoma Patients
    S. Kruijff
    E. Bastiaannet
    A. C. Muller Kobold
    R. J. van Ginkel
    A. J. H. Suurmeijer
    H. J. Hoekstra
    Annals of Surgical Oncology, 2011, 18 : 331 - 331
  • [26] S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma
    Hatpio, R
    Einarsson, R
    CLINICAL BIOCHEMISTRY, 2004, 37 (07) : 512 - 518
  • [27] Elevated serum levels of S100 and survival in metastatic malignant melanoma
    J Buer
    M Probst
    A Franzke
    S Duensing
    J Haindl
    M Volkenandt
    F Wittke
    R Hoffmann
    A Ganser
    J Atzpodien
    British Journal of Cancer, 1997, 75 : 1373 - 1376
  • [28] Elevated serum levels of S100 and survival in metastatic malignant melanoma
    Buer, J
    Probst, M
    Franzke, A
    Duensing, S
    Haindl, J
    Volkenandt, M
    Wittke, F
    Hoffmann, R
    Ganser, A
    Atzpodien, J
    BRITISH JOURNAL OF CANCER, 1997, 75 (09) : 1373 - 1376
  • [29] Comparison of two prognostic markers for malignant melanoma:: MIA and S100 β
    Juergensen, A
    Holzapfel, U
    Hein, R
    Stolz, W
    Buettner, R
    Bosserhoff, AK
    TUMOR BIOLOGY, 2001, 22 (01) : 54 - 58
  • [30] Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma
    Bolander, Asa
    Agnarsdottir, Margret
    Wagenius, Gunnar
    Stromberg, Sara
    Ponten, Fredrik
    Ekman, Simon
    Brattstrom, Daniel
    Larsson, Anders
    Einarsson, Roland
    Ullenhag, Gustav
    Hesselius, Patrik
    Bergqvist, Michael
    MELANOMA RESEARCH, 2008, 18 (06) : 412 - 419